Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.

Authors:
Address: Department of Veterinary Medicine, United States Army Medical Component-Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), Bangkok, Thailand.
Journal:


Publication:

abstract

Immune sera from volunteers vaccinated in a blinded Phase 3 clinical trial with JE-VAX(®) and a new Japanese encephalitis virus (JEV) vaccine (IC51 or IXIARO), were tested for the ability to protect mice against lethal JEV challenge. Sera from IXIARO vaccinated subjects were pooled into four batches based on neutralizing antibody measured by plaque reduction neutralization test (PRNT(50) titer): high (∼200), medium (∼40-50), low (∼20) and negative (<10). Pooled sera from JE-VAX(®) vaccinated subjects (PRNT(50) titer∼55) and pooled JEV antibody negative pre-vaccination sera were used as controls. Groups of ten 6- to 7-week-old female ICR mice were injected intraperitoneally with 0.5 ml of each serum pool diluted 1:2 or 1:10, challenged approximately 18 h later with a lethal dose of either JEV strain SA14 (genotype III) or strain KE-093 (genotype I) and observed for 21 days. All mice in the non-immune serum groups developed clinical signs consistent with JEV infection or died, whereas high titer sera from both IXIARO and JE-VAX(®) sera protected 90-100% of the animals. Statistical tests showed similar protection against both JEV strains SA14 and KE-093 and protection correlated with the anti-JEV antibody titer of IXIARO sera as measured by PRNT(50). Ex vivo neutralizing antibody titers showed that almost all mice with a titer of 10 or greater were fully protected. In a separate study, analysis of geometric mean titers (GMTs) of the groups of mice vaccinated with different doses of IXIARO and challenged with JEV SA14 provided additional evidence that titers≥10 were protective.

Copyright © 2011 Elsevier Ltd. All rights reserved.



Related Articles
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
Vaccine. 2004
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett AD. Vaccine. 2004 Sep 9; 22(27-28):3722-6.
Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
Vaccine. 2008
Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
Fei-fei G, Jian W, Feng X, Li-ping S, Quan-yun S, Jin-ping Z, Pu-yan C, Pei-hong L. Vaccine. 2008 Oct 16; 26(44):5590-4. Epub 2008 Aug 30.
Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
Chin Med J (Engl). 2003
Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
Jia L, Wang Z, Yu Y. Chin Med J (Engl). 2003 Jun; 116(6):941-3.
Review Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
Vaccine. 2000
Review Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
Markoff L. Vaccine. 2000 May 26; 18 Suppl 2:26-32.
Review IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Expert Rev Vaccines. 2010
Review IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB, Vrati S. Expert Rev Vaccines. 2010 Dec; 9(12):1371-84.
DnaJ homolog Hdj2 facilitates Japanese encephalitis virus replication.
Virol J. 2011
DnaJ homolog Hdj2 facilitates Japanese encephalitis virus replication.
Wang RY, Huang YR, Chong KM, Hung CY, Ke ZL, Chang RY. Virol J. 2011 Oct 14; 8:471. Epub 2011 Oct 14.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.